Abstract
Smoking has become one of the most destructive habits that humans have ever participated in. To address the issue, various therapies have been developed over the years that have targeted the major addictive component of smoking, nicotine. These therapies have struggled to address the growing epidemic due to their numerous and well-known limitations; however, currently, there is no go-to treatment plan for nicotine addiction. An alternative, less known form of therapy for nicotine addiction, immunopharmacotherapy, is currently in development and has shown exceptional promise in past animal studies. Vaccine candidates that have arisen from these studies have ultimately met failure in clinical trials, however, due to the lack of observed efficacy in the majority of study participants. Undeterred, current nicotine vaccine research continues and focuses on overcoming the limitations observed in previous vaccines through the optimization of existing technologies and the implementation of novel ideas. It seems likely that with enough time, support, and collaboration, an effective nicotine vaccine will someday make it to the market.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call